Corino Therapeutics

Corino Therapeutics is a private, development-stage biopharmaceutical company focused on acquiring, developing, and commercializing innovative products for the treatment of various human diseases, particularly orphan conditions. Corino has developed technologies that address significant unmet medical needs and offer improved, cost-effective alternatives to current treatment methods. Preclinical and early clinical data indicate that Corino’s lead product candidate, CRX-1008, may provide a safe and effective treatment for all forms of Transthyretin Amyloidosis (ATTR). With nearly 20 years of approval, the active compound in CRX-1008 has extensive safety and toxicity data. Additionally, the compound's efficacy has been validated in new endpoints for ATTR.